
Cardio-Vascular Pharmacology

Dr. Shadi HOMSI

25-8-2016




A- Inhibitors of the Renin-Angiotensin System


HF leads to activation of the RAAS via two mechanisms:

 increased renin release by juxtaglomerular cells in renal afferent arterioles due to diminished renal perfusion pressure produced by the failing heart and
renin release by juxtaglomerular cells promoted by sympathetic stimulation and activation of β receptors.

> The production of angiotensin II, a potent vasoconstrictor, and the subsequent stimulation of aldosterone release that causes salt and water retention lead to increases in both preload and afterload that are characteristic of the failing heart.

➢ In addition, high levels of angiotensin II and of aldosterone have direct detrimental effects on the cardiac muscle, favoring remodeling, fibrosis, and inflammatory changes.







➤ The ACE inhibitors, such as *enalapril and lisinopril*, are recommended as **first-line treatment** of hypertension in patients with a variety of compelling indications, including high coronary disease risk or history of <u>diabetes</u>, stroke, heart failure, myocardial infarction, or <u>chronic kidney disease</u>.

ACE inhibitors are a part of standard pharmacotherapy in HF. These drugs block the enzyme that cleaves angiotensin I to form the potent vasoconstrictor angiotensin II.

> They also diminish the inactivation of bradykinin.


> Vasodilation occurs as a result of decreased levels of the vasoconstrictor angiotensin II and increased levels of bradykinin (a potent vasodilator).

> By reducing angiotensin II levels, ACE inhibitors also decrease the secretion of aldosterone.

1-Angiotensin-converting enzyme inhibitors

A. Actions on the heart:

- > The ACE inhibitors lower BP by reducing peripheral vascular resistance without reflexively increasing cardiac output, heart rate, or contractility.
- ACE inhibitors decrease vascular resistance (afterload) and venous tone (preload), resulting in increased cardiac output.
- ACE inhibitors also blunt the usual angiotensin II-mediated increase in epinephrine and aldosterone seen in HF.





Slow the progression of diabetic nephropathy and decrease albuminuria and, thus, have a <u>compelling indication for use in patients with diabetic nephropathy</u>.

ACE inhibitors are a standard in the care of a patient <u>following a myocardial</u> <u>infarction</u> and <u>first-line agents</u> in the treatment of patients with <u>systolic dysfunction</u>.

➤ ACE inhibitors are first-line drugs for treating <u>heart failure (asymptomatic and</u> symptomatic HF), hypertensive patients with <u>chronic kidney disease</u>, and patients at increased risk of <u>coronary artery disease</u>.

Depending on the severity of HF, ACE inhibitors may be used in combination with diuretics, β-blockers, *digoxin*, *aldosterone antagonists*, *and hydralazine/isosorbide dinitrate fixed-dose combination*. 1- Angiotensin-converting enzyme inhibitors

C. Pharmacokinetics:

> ACE inhibitors are adequately absorbed following oral administration.

Food may decrease the absorption of captopril, so it should be taken on an empty stomach.

Except for *captopril*, ACE inhibitors are <u>prodrugs</u> that require activation by hydrolysis via hepatic enzymes.

<u>Renal elimination</u> of the active moiety is important for most ACE inhibitors except *fosinopril*.

> <u>*Plasma half-lives*</u> of active compounds vary from 2 to 12 hours.

> *Enalaprilat* is the only drug in this class available intravenously.

1- Angiotensin-converting enzyme inhibitors

D. Adverse effects

Common side effects: dry cough, rash, fever, altered taste, postural hypotension and hyperkalemia.

> Angioedema is a rare but potentially life-threatening reaction.

> ACE inhibitors can induce fetal malformations and should not be used by pregnant women.

9

2- Angiotensin-receptor blockers

11

The ARBs, such as *losartan and irbesartan*: <u>alternatives to the ACE inhibitors</u> in patients with severe cough or angioedema.

▶ <u>Block the AT₂ receptors</u>, ↓ ↓ the activation of AT₂ receptors by angiotensin II.

> Their <u>pharmacologic effects</u> are similar to those of ACE inhibitors.

They may be used as first-line agents for the treatment of <u>HT (hypertension</u>), especially in patients with diabetes, heart failure, or chronic kidney disease.

Adverse effects and drug interaction profile are similar to those of ACE inhibitors with decreased risks of cough and angioedema (ARBs do not increase bradykinin levels).

> ARBs should not be combined with an ACE inhibitor.

These agents are also teratogenic and should not be used by pregnant women. 12



Pharmacokinetics:

- Orally active drugs and require only once-a-day dosing
- Losartan undergoes extensive first-pass hepatic metabolism, including

conversion to its active metabolite. The other drugs have inactive metabolites.

Elimination of metabolites and parent compounds occurs in the urine and feces

3- RENIN INHIBITOR

Aliskiren (selective renin inhibitor) directly inhibits renin and, thus, acts earlier in the RAAS than ACE inhibitors or ARBs.

It lowers blood pressure about as effectively as ARBs, ACE inhibitors, and thiazides.

> Aliskiren should not be combined with an ACE inhibitor or ARB.

Aliskiren can cause diarrhea, especially at higher doses, and can also cause cough and angioedema, but probably less often than ACE inhibitors.

Aliskiren is contraindicated during pregnancy.

Aliskiren is metabolized by CYP 3A4.

13

4-Aldosterone antagonists

Spironolactone is a direct antagonist of aldosterone, thereby preventing salt retention, myocardial hypertrophy, and hypokalemia

Eplerenone is a competitive antagonist of aldosterone at mineralocorticoid receptors.

> Aldosterone antagonists are indicated in patients with more severe stages of HF and recent myocardial infarction.